All News

alveolar hemorrhage acute

Alveolar Hemorrhage and Mortality in Lupus

d Jack Cush, MD

Metanalysis of patients with diffuse alveolar hemorrhage (DAH), show this to be a rare and life-threatening complication of systemic lupus erythematosus (SLE), that is more apt to affect older, severe lupus patients with active infection.

Read Article
T%20cell.jpg

Checkpoint Inhibitor Use with Pre-existing Autoimmune Disease

d Jack Cush, MD

Annals of Internal Medicine reports treating advanced melanoma with immune checkpoint inhibitors (ICI) in patients with pre-existing autoimmune disease (AID) was as effective and safe in those with AID compared to those without AID, although severe colitis occurred more frequently among pati

Read Article
RWCS 2021 card

RWCS Highlights - Day 4

d Rachel Tate, DO

As another year at RWCS in Maui wrapped up, I’m so thankful I had the opportunity to participate remotely. Here are my day 4 #RWCS2021 pearls from the Novel Therapies Year in Review (RA, SLE, OA); novel concepts in pediatric rheumatology; and post-COVID telerheumatology sessions.

Read Article
eye%20exa.jpg (keep)

ACR and Three Societies Agree on HCQ Eye Safety

d MedPage Today

Four major medical societies issued a joint statement of principles on safe use of hydroxychloroquine from the perspective of ocular toxicity.

Read Article
gout podagra inflammed

MIRROR Study: Pegloticase With Methotrexate in Uncontrolled Gout

d Jack Cush, MD

Botson et al has reported that the combination of methotrexate (MTX) and IV pegloticase is safe and effective in patients with uncontrolled gout.

This exploratory, open-label clinical trial screened 17 patients and treated 14 patients (all men, 49.3 ± 8.7 years) with IV pegloticase with MTX (15 mg/week) and folic acid (1 mg/day) 4 weeks prior to and throughout pegloticase treatment.

Read Article
rwcsmtg.jpeg

RWCS Highlights - Day 3

d Rachel Tate, DO

Day 3 report from the 2021 RWCS meeting in Maui (and virtually) includes pearls from the PsA 2020 Year in Review; fact vs. fiction on evidence based medicine: diet and rheumatic diseases; hot topics in allergy/immunology; and pediatric rheumatology highlights.

Read Article
Italian IBD clinic with 90 IBD Vedolizumab Tx pts, 8%(11) developed severe enthesitis (4 Multifocal, 6 unifocal). Sxs after mean 46 wks, CRP=5.1 mg/dl, majority HLA-B27 negative; confirmed by PD/UA in 7 - 4/7 developed post-inflam entheseal calcifications https://t.co/uwAJM8giBX

Links:

Dr. John Cush RheumNow ( View Tweet)

Common mucocutaneous findings in 35 kids w/ MIS-C & COVID: 1) conjunctival injection (21), palmoplantar erythema (18), lip hyperemia (17), periorbital erythema/edema (7), strawberry tongue (8), & malar erythema (6) https://t.co/mcSOXtXaEh

Links:

Dr. John Cush RheumNow ( View Tweet)

RWCS Highlights - Day 4 from Dr. Rachel Tate ( @uptotate) -Novel Therapies Year in Review (RA, SLE, OA) -Novel concepts in Pediatric Rheumatology -TeleRheumatology Update: Post-COVID, Pre-?? https://t.co/JoTV25suxD https://t.co/Id19zgRT37

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR and Three Societies Agree on HCQ Eye Safety Four major medical societies issued a joint statement of principles on safe use of hydroxychloroquine from the perspective of ocular toxicity. https://t.co/3ALK3MpOen https://t.co/SzScNXgoqn

Links:

Dr. John Cush RheumNow ( View Tweet)
MIRROR Study: Pegloticase With Methotrexate in Uncontrolled Gout Botson et al has reported that the combination of methotrexate (MTX) and IV pegloticase is safe and effective in patients with uncontrolled gout. https://t.co/DRkIMOAhs4 https://t.co/2dft1QjC6E

Links:

Dr. John Cush RheumNow ( View Tweet)
30 #RA pts treated w/ tofacitinib x 12 mos w/ signif improvement in DAS28, CRP, & HAQ and attenuation of further bone loss, as measured by significantly increased osteocalcin, OPG, and vitamin D3, with decreased CTX levels correlating w/ DXA results https://t.co/RSXL38cJvs

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Lindsey A. Criswell was sworn in this morning as the new director of NIAMS. https://t.co/4LxsX9Lh1W
NIAMS/NIH/DHHS NIH_NIAMS ( View Tweet)
🔥 Increased baseline prevalence and 40% higher risk of developing #Multimorbidity after #RA incidence/index vs general population @CrowsonCindy @JohnDavisIII #MayoClinicRheumatology ⁦@jrheum⁩ ⁦@NIAMSFunding⁩ ⁦@NIH⁩ https://t.co/8GolTowAGm

Links:

Elena MyasoedovaMD MyasoedovaElena ( View Tweet)

Consults in Cars--Is this the future of telehealth? https://t.co/INbKZ3xxty https://t.co/9Wj2eXy71l

Links:

Dr. John Cush RheumNow ( View Tweet)
Download Available--TNF Inhibitor -Cycle TNFi or Switch MOA? https://t.co/PgmTDYltpX

Links:

Dr. John Cush RheumNow ( View Tweet)

RWCS Highlights - Day 3 -Psoriatic Arthritis -Evidence Based Medicine: Diet and Rheumatic Diseases -Hot topics in Allergy/Immunology -Pediatric Rheumatology – past, present, and future https://t.co/CaKAyhxId3 https://t.co/5m882bcTOo

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective study of 162 early RA pts looked at Xrays (baseline & 5 yrs). RF & ESR predicted erosion & JSN progression; CCP predicted erosions; Smoking & high DAS28 > 5.1 predicted progression of erosions. Obesity negatively predicted JSN progression https://t.co/fue121hHVw

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of Systemic Sclerosis patients from the EUSTAR database: shows of the 144 with anti-PM/Scl+ Abs, there was an increased risk of muscle involvement, ILD, calcinosis and dermatomyositis; muscle involvement had a more severe disease phenotype. https://t.co/ORA2y1BWgn

Links:

Dr. John Cush RheumNow ( View Tweet)

Join us at RheumNow Live next month in Texas or virtually! CME credits available. https://t.co/uwxOVh142F https://t.co/58BvLesevP

Links:

Dr. John Cush RheumNow ( View Tweet)
×